<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>35283</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2407-1-6</infon><infon key="article-id_pmc">35283</infon><infon key="article-id_pmid">11472637</infon><infon key="article-id_publisher-id">1471-2407-1-6</infon><infon key="fpage">6</infon><infon key="journal-title">BMC Cancer</infon><infon key="lpage">6</infon><infon key="name_0">surname:Tan;given-names:Dong-Feng</infon><infon key="name_1">surname:Huberman;given-names:Joel A</infon><infon key="name_2">surname:Hyland;given-names:Andrew</infon><infon key="name_3">surname:Loewen;given-names:Gregory M</infon><infon key="name_4">surname:Brooks;given-names:John SJ</infon><infon key="name_5">surname:Beck;given-names:Amy F</infon><infon key="name_6">surname:Todorov;given-names:Ivan T</infon><infon key="name_7">surname:Bepler;given-names:Gerold</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">1</infon><infon key="year">2001</infon><offset>0</offset><text>MCM2 - a promising marker for premalignant lesions of the lung: a cohort study</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>79</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>90</offset><text>The use of marker proteins specific to proliferating cells during cancer progression can aid in the detection of premalignant lesions. In 41 bronchial biopsy specimens, we compared the susceptibility of Ki-67 with MCM2, as these cells were specifically found in various parts of the body.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>461</offset><text>Techniques</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>469</offset><text>Parallel sections were stained with MCM2 and Ki-67 antibodies, and the frequencies of each staining were independently measured by two investigators. The statistical tests performed using the two-sided correlated samples t-test and Wilcoxon rank sum test to evaluate differences.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>737</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>745</offset><text>The staining frequency of anti-MCM2 (39%) was significantly higher than that of the anti&#8211;Ki-67 (6%) in 41 specimens, with a significant difference (p  0.001) between the two. In contrast, antimimum2 detected cells close to the epithelial surface in metaplastic lesions, while antimiecM 2 did not.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1006</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1018</offset><text>We find that MCM2 is detectable in premalignant lung cells that are 2-3 times more proliferating than Ki-67. The fact that it is present in cells at the surface of metaplastic lung lesions, which are more likely to be exfoliated into sputum, lends support to its use as an early marker for significantly enhancing lung cancer survival rates through anti-MCM2 therapy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1490</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1503</offset><text>The lung is a major organ of the body and major organ of the immune system. The lung is a central organ of the immune system and plays a significant role in a wide range of diseases, including asthma, allergies, chronic obstructive pulmonary disease (COPD), chronic obstructive pulmonary disease (COPD), and various types of cancer, and is often the first line of defense against many of these diseases. Lung cancer is the second most common cause of death in men, and lung cancer is the most common cause of death in women. Lung cancer is the second leading cause of cancer mortality in the world. Lung cancer is a leading cause of lung cancer-related deaths globally.1,2

Cancer is a chronic disease in which the cancer cells in the body proliferate and grow</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2815</offset><text>Therefore, it is necessary to develop methods for detecting bronchial mucosal abnormalities that are precursors to lung cancer before systemic shedding of tumor cells occurs (these precursor lesion types may also appear after tumour growth and after the removal of some other potentially benign lesions), such as metaplasia, dyspnea or carcinoma in situ (CIS), which are thought to represent progressive histologic causes of squamous cell carcinoma.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3317</offset><text>According to current data, 23% of current and former smokers have metaplastic lesions, while 2% have dysplastic deseases. However, not all cesions develop lung cancer. Smoking cessation, which can be viewed as an active intervention, appears to decrease metaplasia rates from 27% to 7% in former patients. It is estimated that 50% of CIS will progress to non-invasive cancer over 6 months, but 4 patients who underwent regular bronchoscopy at 6-month intervals developed lung tumors</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4345</offset><text>One potential solution to these questions is the development of specific immunohistochemical markers that can enhance the sensitivity and reliability of current methods used to detect precursor lesions in histologic and cytologic specimens. As a result, proliferation is essential for lung cancer development, and the use of markers specific to cell proliferation should be considered.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4749</offset><text>Proliferating cell nuclear antigen (PCNA) and Ki-67 have been extensively researched in this context. PCNA is a homotrimeric protein that binds to DNA and proteins involved in DNA replication and repair, and is essential for DNA proliferation. However, due to its importance as an epitope of nascent nuclear protein recognized by the MIB-1 monoclonal antibody, Ki-609 is frequently expressed throughout the cell cycle of proliferous cells. Immunohistochemical studies suggest that increased lung tumor marker markers can indicate decreased survival.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5949</offset><text>We have presented results from our comparison of Ki-67 and a new proliferation marker, MCM2, along with evidence that the latter is also detectable in proliferating cells. MCFs are responsible for limiting DNA replication to one round per cell cycle and can act as 'licensing factors' For example, immunoglobulin A (IBSA) may be used by certain cancer models to detect human breast cancer, while others have found evidence similar to this.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>7066</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7074</offset><text>Study population</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7091</offset><text>MCM2 and Ki-67 expression in bronchial biopsy specimens from patients at risk for lung cancer or with suspected lung cancer were studied by immunohistochemistry (IHC). We reviewed all pathology specimens from 106 patients that had undergone bronchoscopy with standard white light and laser-induced fluorescence at Roswell Park Cancer Institute from March 1998 to March 2000. Fourteen of these 106 patients were selected for further analysis based on the presence of abnormal morphology and the availability of multiple specimen blocks (4-17 per patient) for investigations. Of these 14 patients, the highest degree of abnormality in 4 was metaplasia, in 4 dysplasia, in 3 CIS, in 1 invasive squamous cell carcinoma, and in 2 invasive adenocarcinoma. Five of these patients were Caucasian women, 1 was an African-American man, and 8 were Caucasian men. All were active or former smokers.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7978</offset><text>Sample preparation and selection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8011</offset><text>From each specimen block, 5 serial 4-&#956;m sections were cut and placed on charged glass slides. Sections 1-4 were used for IHC, and section 5 was stained with hematoxylin and eosin. This latter section was reviewed and compared with the original slide used for diagnostic purposes. In 41 specimens, the morphology was comparable between the original slide and slide 5. These 41 specimens were used for IHC analysis and included morphologically normal bronchial mucosa, metaplasia, dysplasia, and CIS (see Table 1 for the numbers of specimens with normal and abnormal morphology).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>8590</offset><text>Percentage and intensity of staining for MCM2 and Ki-67 in normal bronchial mucosa and premalignant lesions</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Type of&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Number of&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;% Cells Positive&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;% Cells Positive&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Mean&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Mean&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Specimen&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Specimens&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;for MCM2&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;for Ki-67&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Intensity for&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Intensity&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;bold&gt;Mean (Range)&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;Mean (Range)&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;MCM2&lt;sup&gt;a&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;for Ki-67&lt;sup&gt;a&lt;/sup&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Normal Mucosa&lt;/td&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;td align="left"&gt;11&lt;sup&gt;b,e&lt;/sup&gt; (5-20)&lt;/td&gt;&lt;td align="left"&gt;3&lt;sup&gt;b,f&lt;/sup&gt; (1-5)&lt;/td&gt;&lt;td align="left"&gt;1.6&lt;sup&gt;i&lt;/sup&gt; (1.0-2.0)&lt;/td&gt;&lt;td align="left"&gt;1.6&lt;sup&gt;i&lt;/sup&gt; (1.0-2.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Metaplasia&lt;/td&gt;&lt;td align="left"&gt;21&lt;/td&gt;&lt;td align="left"&gt;39&lt;sup&gt;c,e&lt;/sup&gt; (7-90)&lt;/td&gt;&lt;td align="left"&gt;14&lt;sup&gt;c,f&lt;/sup&gt; (1-60)&lt;/td&gt;&lt;td align="left"&gt;2.3&lt;sup&gt;i&lt;/sup&gt; (1.0-3.0)&lt;/td&gt;&lt;td align="left"&gt;2.3&lt;sup&gt;i&lt;/sup&gt; (1.0-3.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Dysplasia&lt;/td&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;td align="left"&gt;64&lt;sup&gt;d,e,g&lt;/sup&gt; (40-100)&lt;/td&gt;&lt;td align="left"&gt;34&lt;sup&gt;d,f&lt;/sup&gt; (7-40)&lt;/td&gt;&lt;td align="left"&gt;2.6&lt;sup&gt;i&lt;/sup&gt; (2.0-3.0)&lt;/td&gt;&lt;td align="left"&gt;2.8&lt;sup&gt;i&lt;/sup&gt; (2.0-3.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CIS&lt;/td&gt;&lt;td align="left"&gt;6&lt;/td&gt;&lt;td align="left"&gt;39&lt;sup&gt;e,g&lt;/sup&gt; (5-60)&lt;/td&gt;&lt;td align="left"&gt;17&lt;sup&gt;f,h&lt;/sup&gt; (3-60)&lt;/td&gt;&lt;td align="left"&gt;2.4&lt;sup&gt;i&lt;/sup&gt; (2.0-3.0)&lt;/td&gt;&lt;td align="left"&gt;2.3&lt;sup&gt;i&lt;/sup&gt; (1.0-3.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Combined data&lt;/td&gt;&lt;td align="left"&gt;41&lt;/td&gt;&lt;td align="left"&gt;39&lt;sup&gt;c&lt;/sup&gt;(5-100)&lt;/td&gt;&lt;td align="left"&gt;16&lt;sup&gt;c&lt;/sup&gt; (1-60)&lt;/td&gt;&lt;td align="left"&gt;2.2 (1.0 - 3.0)&lt;/td&gt;&lt;td align="left"&gt;2.3 (1.0-3.0)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>8698</offset><text>Type of	Number of	% Cells Positive	% Cells Positive	Mean	Mean	 	Specimen	Specimens	for MCM2	for Ki-67	Intensity for	Intensity	 			Mean (Range)	Mean (Range)	MCM2a	for Ki-67a	 	Normal Mucosa	7	11b,e (5-20)	3b,f (1-5)	1.6i (1.0-2.0)	1.6i (1.0-2.5)	 	Metaplasia	21	39c,e (7-90)	14c,f (1-60)	2.3i (1.0-3.0)	2.3i (1.0-3.0)	 	Dysplasia	7	64d,e,g (40-100)	34d,f (7-40)	2.6i (2.0-3.0)	2.8i (2.0-3.0)	 	CIS	6	39e,g (5-60)	17f,h (3-60)	2.4i (2.0-3.0)	2.3i (1.0-3.0)	 	Combined data	41	39c(5-100)	16c (1-60)	2.2 (1.0 - 3.0)	2.3 (1.0-3.0)	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>9227</offset><text>a The intensity of stain ranges from 0 (absent) to 3 (strong). b p-value &lt; 0.016 for the paired difference t-test and Wilcoxon sign rank test. c p-value &lt; 0.001 for the paired difference t-test and Wilcoxon sign rank test. d p-value &lt; 0.034 for the paired difference t-test and &lt;0.063 for the Wilcoxon sign-rank test. e p-value &lt;0.010 for the ANOVA and Kruskal-Wallis tests of differences in MCM2 category means. f p-value &lt;0.001 for the ANOVA and Kruskal-Wallis tests of differences in Ki-67 category means. g p-value &lt;0.080 for the independent samples t-test between dysplasia and CIS within MCM2. h p-value &lt;0.117 for the independent samples t-test between dysplasia and CIS within Ki67. i p-value &lt;0.004 for the ANOVA and Kruskal-Wallis tests of differences in MCM2 and Ki-67 category means.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10023</offset><text>Immunohistochemistry</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10044</offset><text>Sections were stained with polyclonal rabbit antibodies raised and affinity-purified against the N-terminal portion of MCM2. Parallel sections were stained with the MIB-1 mouse monoclonal antibody against Ki-67 (DAKO, Carpinteria, California). IHC was performed as described earlier. Briefly, sections were deparaffinized, and those to be stained with Ki-67 were subjected to microwave antigen retrieval in citrate buffer for 10 minutes, twice. Antigen retrieval was not required for MCM2. MIB-1 was used at a dilution of 1:50. The MCM2 antibody was used at a dilution of 1:500. The avidin-biotin detection method was employed on a Ventana Automated System (Tucson, Arizona). An irrelevant rabbit antiserum served as a negative control. Percentage, intensity, and distribution of stained cells were analyzed and scored for each antibody independently by two of the authors (DFT, JAH) with similar results.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10950</offset><text>Statistical Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10971</offset><text>The percent of cells stained for each sample was estimated as a continuous number ranging from 0 to 100. The staining intensity was categorically coded as 0 (absent), 1 (weak), 2 (moderate), or 3 (strong). The average of both the percent of cells stained and staining intensity was calculated for each type of specimen (normal mucosa, metaplasia, dysplasia, CIS). To test for differences between the staining characteristics of MCM2 and Ki-67 both the parametric paired samples t-test and the non-parametric Wilcoxon rank-sum test were performed. To test for differences across specimen classes (normal mucosa, metaplasia, dysplasia and CIS) for each stain (Ki-67 or MCM2), the analysis of variance method as well as the non-parametric Kruskal-Wallis tests were used. To test specifically for differences between dysplasia and CIS for each stain, the independent samples t-test and the Mann-Whitney tests were performed. Both parametric and non-parametric tests were used because the distributional assumptions required for parametric testing may not be satisfied in all cases. All statistical tests assumed a two-sided alternative with a 5% level of significance.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>12136</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12144</offset><text>In normal bronchial mucosa, antibodies against both proteins, MCM2 and Ki-67, generated similar patterns: some cells in the basal and parabasal layer of the bronchial epithelium displayed immunoreactivity (Fig. 1). The proportion of cells staining for MCM2 was significantly (p &lt; 0.02) greater than for Ki-67 (Table 1). In both cases, the intensity of nuclear staining was variable.</text></passage><passage><infon key="file">1471-2407-1-6-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>12527</offset><text>Comparisons of staining by anti-MCM2 and anti-Ki-67 in parallel sections of normal bronchial mucosa and premalignant lung lesions. All objective lens magnifications were 20&#215; except for the upper panels of normal bronchial mucosa and metaplasia, which were 40&#215;.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12790</offset><text>In premalignant lesions, evaluation of the staining by the two antibodies (Table 1) revealed significantly (p &lt; 0.001) more frequent staining of nuclei within metaplastic lesions by antibodies against MCM2 than by antibodies against Ki-67. We also noticed that, in metaplasia, anti-MCM2 frequently stained both basal cells and cells throughout the entire thickness of the epithelium, while anti-Ki-67 primarily stained basal cells and cells in the lower half of the epithelium (Fig. 1, lower of the two "metaplasia" panels). Although the number of samples of dysplasia and CIS was too low to permit statistical evaluation of the differences between the two antibodies, we noticed that in every case of dysplasia or CIS, the frequency of cells stained by anti-MCM2 was as high or higher than the frequency of staining by anti-Ki-67. In fact, the same relationship was evident in the normal mucosa and metaplasia samples. Consequently, when the data for all 41 samples were combined, the difference in staining frequency between anti-MCM2 and anti-Ki-67 was highly significant (p &lt; 0.001; Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13887</offset><text>We observed variable staining in premalignant lesions. In many cases, within single lesions some regions stained while others did not, and the intensity of staining was variable from region to region and from cell to cell within regions. The level of variability was similar for both markers (Fig. 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14189</offset><text>In the progression from normal mucosa to metaplasia to dysplasia, the results obtained with both antibodies suggested differences in staining frequency and intensity. For both antibodies, the mean percentages of cells stained and staining intensity were different across specimen categories (all p-values &lt;0.010) and increased from normal mucosa to metaplasia and from metaplasia to dysplasia. Although the sample numbers are too low to draw a firm conclusion, the data suggest a possible decrease in staining frequency by both antibodies in the transition from dysplasia to CIS (p = 0.117 for Ki-67 and p = 0.080 for MCM2) (Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14824</offset><text>No significant differences were detected between the average stain intensities produced by the two antibodies (Fig. 1; Table 1).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>14953</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14964</offset><text>This is the first comparison of MCM2 and Ki-67 expression in premalignant lesions of the human lung, and it showed that MCM2 was expressed in a greater percentage of cells in normal mucosa and in premalignant lesions than Ki-67. The proportion of cells stained for MCM2 ranged from 5% to 100% and for Ki-67 from 1% to 60% (Table 1). The average percentage of cells stained for MCM2 (11-64%) was higher than that for Ki-67 (3-34%). Statistical analyses of the frequencies of positively stained cells were done with the paired samples t-test and the Wilcoxon sign rank test. Both tests showed a striking difference (p &lt; 0.001) in immunoreactivity between these markers across all 41 samples. This finding suggests that MCM2 may prove to be a more sensitive intermediate marker for lung cancer risk than Ki-67.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15772</offset><text>However, there are several caveats to the use of MCM2 for assessing lung cancer risk. Most importantly, the ability of cells to proliferate, even though a hallmark of malignancy, is also a component of inflammation and healing. Thus, metaplastic lesions are frequently associated with chronic inflammation as exemplified by the presence of such lesions in 27% of current smokers but only 7% of former smokers. Furthermore, even high-grade dysplasia does not necessarily lead to invasive cancer. The fact that anti-MCM2 more frequently stains metaplastic cells at the epithelial surface suggests that it is more likely than anti-Ki-67 to detect exfoliated proliferating epithelial cells in cytological specimens such as sputum. However, this presumably higher sensitivity for premalignant cells could be accompanied by an unacceptably low specificity. Therefore, it is important to assess the positive predictive value of both markers, MCM2 and Ki-67, for lung cancer risk in cytologic and histologic specimens from a defined population at risk for this disease in a prospective study.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16857</offset><text>Second, there has been a shift in the predominant type of lung cancer from squamous cell carcinoma to adenocarcinoma in the United States over the past twenty years. Since adenocarcinomas predominantly arise in the periphery of the lung and less frequently in the larger and more easily accessible airways, the utility of assessing morphological, molecular, and proliferative changes in these larger airways may be called into question. During the 1970s three randomized lung cancer screening trials were conducted in the US, and each of these trials used sputum cytology as one of the means to detect lung cancer at an early stage. Aside from the major finding that screening did not reduce lung cancer mortality, several other important facts were uncovered. These included the findings that lung cancers detected by sputum cytology only, compared to chest X-ray only, had a higher rate of complete resectability (83% vs. 62%) and a higher 5-year survival rate (80% vs. 40%); that approximately one-third of the cancers detected by sputum cytology were adenocarcinomas and two-thirds were squamous cell carcinomas; that sputum cytology detected 36% of all incident cases of lung cancer (excluding interval cases); and that sputum cytology detected 6/40 adenocarcinomas. It can thus be concluded that cytological examination of sputum specimens is able to detect adenocarcinomas at an early stage albeit with low sensitivity (15%). Staining of sputum specimens for proliferation markers, such as MCM2 and Ki-67, may increase that sensitivity by focusing the pathologist's attention on proliferating cells. In addition to its potential for detecting frank malignancy, staining for proliferation markers may also provide an estimate of the frequency of potentially precancerous conditions (metaplasia and dysplasia) in the patient's airways. This estimate may be helpful for determining whether to initiate other more costly evaluations for lung cancer detection.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18820</offset><text>Third, since MCM2 and Ki-67 are both markers of cellular proliferation and required for cell cycle progression, the fact that anti-MCM2 stained a larger number of cells than anti-Ki-67 in every specimen examined suggests that Ki-67 may be expressed during a shorter interval of the cell cycle than MCM2. MCM2 is present throughout the cell cycle, while Ki-67 is predominantly expressed during S, G2 and M phase. Variability of cell cycle time in mammalian cells is largely a result of differences in the duration of G1 phase. Thus, specimens that consist of a relatively slow growing population of cells and consequently a higher proportion of cells in G1 phase would show staining of more cells with MCM2 than Ki-67.  Conversely, specimens with cells dividing at a high rate would show staining of near equal numbers of cells for MCM2 and Ki-67. Thus it is likely that staining for both, MCM2 and Ki-67, will provide information about cell cycle distribution and possibly growth dynamics not obtainable by staining for either marker alone.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19861</offset><text>Finally, the data presented on MCM2 expression by IHC were obtained with affinity-purified polyclonal rabbit antibodies. The supply of these purified antibodies is limited, and their use for MCM2 immunostaining is therefore not uniformly available. Although additional polyclonal antibody preparations can be generated by immunizing more rabbits, the best solution would be the commercial availability of specific MCM2 monoclonal antibodies. Fortunately, several of these are now available and useful for Western blotting and staining of frozen sections. The utility of these antibodies for IHC in paraffin-embedded specimens is being investigated.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20510</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20521</offset><text>We have demonstrated that MCM2 antibodies can provide consistent, reliable staining in fixed tissues without the need for antigen retrieval. The results obtained are easy to interpret as there is a significant difference between normal bronchoepithelium and premalignant lesions, making it an easy-to-use marker that has great potential for assessment of the progression and regression of morphologically abnormal lesIONS in future primary lung cancer prevention studies and for early detection of lung Cancer screening studies.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>21079</offset><text>Competing Interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>21099</offset><text>None Declared</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>21113</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>21137</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="fpage">15</infon><infon key="lpage">36</infon><infon key="name_0">surname:Greenlee;given-names:RT</infon><infon key="name_1">surname:Hill-Harmon;given-names:MB</infon><infon key="name_2">surname:Murray;given-names:T</infon><infon key="name_3">surname:Thun;given-names:M</infon><infon key="pub-id_pmid">11577478</infon><infon key="section_type">REF</infon><infon key="source">CA Cancer J Clin</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2001</infon><offset>21202</offset><text>Cancer statistics, 2001</text></passage><passage><infon key="fpage">1710</infon><infon key="lpage">1717</infon><infon key="name_0">surname:Mountain;given-names:C</infon><infon key="pub-id_pmid">9187198</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">111</infon><infon key="year">1997</infon><offset>21226</offset><text>Revisions in the international system for staging lung cancer</text></passage><passage><infon key="fpage">339</infon><infon key="lpage">350</infon><infon key="name_0">surname:Martini;given-names:N</infon><infon key="name_1">surname:Ginsberg;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">Comprehensive textbook of thoracic oncologyEdited by Aisner J, Arriagada R, Green M, Martini N, Perry M. pp. 339-350. Baltimore: Williams and Williams;</infon><infon key="type">ref</infon><infon key="year">1996</infon><offset>21288</offset><text>Treatment of stage I and II disease</text></passage><passage><infon key="fpage">1568</infon><infon key="lpage">1571</infon><infon key="name_0">surname:Patz;given-names:EF;suffix:Jr</infon><infon key="name_1">surname:Rossi;given-names:S</infon><infon key="name_2">surname:Harpole;given-names:DH;suffix:Jr</infon><infon key="name_3">surname:Herndon;given-names:JE</infon><infon key="name_4">surname:Goodman;given-names:PC</infon><infon key="pub-id_doi">10.1378/chest.117.6.1568</infon><infon key="pub-id_pmid">10858384</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">117</infon><infon key="year">2000</infon><offset>21324</offset><text>Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer</text></passage><passage><infon key="fpage">1627</infon><infon key="lpage">1633</infon><infon key="name_0">surname:Patz;given-names:E</infon><infon key="name_1">surname:Goodman;given-names:P</infon><infon key="name_2">surname:Bepler;given-names:G</infon><infon key="pub-id_doi">10.1056/NEJM200011303432208</infon><infon key="pub-id_pmid">11096172</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">343</infon><infon key="year">2000</infon><offset>21416</offset><text>Early detection and screening for lung cancer</text></passage><passage><infon key="fpage">256</infon><infon key="lpage">270</infon><infon key="name_0">surname:Saccomanno;given-names:G</infon><infon key="name_1">surname:Archer;given-names:VE</infon><infon key="name_2">surname:Auerbach;given-names:O</infon><infon key="name_3">surname:Saunders;given-names:RP</infon><infon key="name_4">surname:Brennan;given-names:LM</infon><infon key="pub-id_pmid">4810100</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1974</infon><offset>21462</offset><text>Development of carcinoma of the lung as reflected in exfoliated cells</text></passage><passage><infon key="fpage">472a</infon><infon key="name_0">surname:Morice;given-names:R</infon><infon key="name_1">surname:Lee;given-names:J</infon><infon key="name_2">surname:Kurie;given-names:J</infon><infon key="name_3">surname:Khuri;given-names:F</infon><infon key="name_4">surname:Ro;given-names:J</infon><infon key="name_5">surname:Kemp;given-names:B</infon><infon key="name_6">surname:Broxson;given-names:A</infon><infon key="name_7">surname:Liu;given-names:D</infon><infon key="name_8">surname:Hong;given-names:W</infon><infon key="section_type">REF</infon><infon key="source">Proc Am Soc Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1999</infon><offset>21532</offset><text>Bronchial squamous metaplasia and dysplasia in current and former smokers</text></passage><passage><infon key="fpage">1572</infon><infon key="lpage">1576</infon><infon key="name_0">surname:Venmans;given-names:B</infon><infon key="name_1">surname:van Boxem;given-names:T</infon><infon key="name_2">surname:Smit;given-names:E</infon><infon key="name_3">surname:Psotmus;given-names:P</infon><infon key="name_4">surname:Sutedja;given-names:T</infon><infon key="pub-id_doi">10.1378/chest.117.6.1572</infon><infon key="pub-id_pmid">10858385</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">117</infon><infon key="year">2000</infon><offset>21606</offset><text>Outcome of bronchial carcinoma in situ</text></passage><passage><infon key="fpage">1685</infon><infon key="lpage">1693</infon><infon key="name_0">surname:Tockman;given-names:MS</infon><infon key="name_1">surname:Gupta;given-names:PK</infon><infon key="name_2">surname:Myers;given-names:JD</infon><infon key="name_3">surname:Frost;given-names:JK</infon><infon key="name_4">surname:Baylin;given-names:SB</infon><infon key="name_5">surname:Gold;given-names:EB</infon><infon key="name_6">surname:Chase;given-names:AM</infon><infon key="name_7">surname:Wilkinson;given-names:PH</infon><infon key="name_8">surname:Mulshine;given-names:JL</infon><infon key="pub-id_pmid">2846790</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1988</infon><offset>21645</offset><text>Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">7</infon><infon key="name_0">surname:Bechtel;given-names:JJ</infon><infon key="name_1">surname:Petty;given-names:TL</infon><infon key="name_2">surname:Saccomanno;given-names:G</infon><infon key="pub-id_doi">10.1016/S0169-5002(00)00190-2</infon><infon key="pub-id_pmid">11008005</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2000</infon><offset>21802</offset><text>Five year survival and later outcome of patients with X-ray occult lung cancer detected by sputum cytology</text></passage><passage><infon key="name_0">surname:Kelman;given-names:Z</infon><infon key="name_1">surname:Hurwitz;given-names:J</infon><infon key="pub-id_pmid">9697409</infon><infon key="section_type">REF</infon><infon key="source">Trends Biochem Sci</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1998</infon><offset>21909</offset><text>Protein-PCNA interactions: a DNA-scanning mechanism?</text></passage><passage><infon key="fpage">23</infon><infon key="lpage">39</infon><infon key="name_0">surname:Tsurimoto;given-names:T</infon><infon key="pub-id_doi">10.1016/S0167-4781(98)00204-8</infon><infon key="pub-id_pmid">9838028</infon><infon key="section_type">REF</infon><infon key="source">Biochim Biophys Acta</infon><infon key="type">ref</infon><infon key="volume">1443</infon><infon key="year">1998</infon><offset>21962</offset><text>PCNA, a multifunctional ring on DNA</text></passage><passage><infon key="fpage">284</infon><infon key="lpage">292</infon><infon key="name_0">surname:Kreitz;given-names:S</infon><infon key="name_1">surname:Fackelmayer;given-names:FO</infon><infon key="name_2">surname:Gerdes;given-names:J</infon><infon key="name_3">surname:Knippers;given-names:R</infon><infon key="pub-id_doi">10.1006/excr.2000.5064</infon><infon key="pub-id_pmid">11082298</infon><infon key="section_type">REF</infon><infon key="source">Exp Cell Res</infon><infon key="type">ref</infon><infon key="volume">261</infon><infon key="year">2000</infon><offset>21998</offset><text>The proliferation-specific human Ki-67 protein is a constituent of compact chromatin</text></passage><passage><infon key="fpage">231</infon><infon key="lpage">237</infon><infon key="name_0">surname:Endl;given-names:E</infon><infon key="name_1">surname:Gerdes;given-names:J</infon><infon key="pub-id_doi">10.1006/excr.2000.4888</infon><infon key="pub-id_pmid">10837136</infon><infon key="section_type">REF</infon><infon key="source">Exp Cell Res</infon><infon key="type">ref</infon><infon key="volume">257</infon><infon key="year">2000</infon><offset>22083</offset><text>The Ki-67 protein: fascinating forms and an unknown function</text></passage><passage><infon key="fpage">513</infon><infon key="lpage">522</infon><infon key="name_0">surname:Schulter;given-names:C</infon><infon key="name_1">surname:Duchrow;given-names:M</infon><infon key="name_2">surname:Wohlenberg;given-names:C</infon><infon key="name_3">surname:Becker;given-names:MH</infon><infon key="name_4">surname:Key;given-names:G</infon><infon key="name_5">surname:Flad;given-names:HD</infon><infon key="name_6">surname:Gerdes;given-names:J</infon><infon key="pub-id_pmid">8227122</infon><infon key="section_type">REF</infon><infon key="source">J Cell Biol</infon><infon key="type">ref</infon><infon key="volume">123</infon><infon key="year">1993</infon><offset>22144</offset><text>The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins</text></passage><passage><infon key="fpage">2219</infon><infon key="lpage">2229</infon><infon key="name_0">surname:Maeshima;given-names:Y</infon><infon key="name_1">surname:Kashihara;given-names:N</infon><infon key="name_2">surname:Sugiyama;given-names:H</infon><infon key="name_3">surname:Makino;given-names:H</infon><infon key="name_4">surname:Ota;given-names:Z</infon><infon key="pub-id_pmid">8915983</infon><infon key="section_type">REF</infon><infon key="source">J Am Soc Nephrol</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1996</infon><offset>22338</offset><text>Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation</text></passage><passage><infon key="fpage">819</infon><infon key="lpage">825</infon><infon key="name_0">surname:Lavezzi;given-names:AM</infon><infon key="name_1">surname:Santambrogio;given-names:L</infon><infon key="name_2">surname:Bellaviti;given-names:N</infon><infon key="name_3">surname:Biondo;given-names:B</infon><infon key="name_4">surname:Nosotti;given-names:M</infon><infon key="name_5">surname:Radice;given-names:F</infon><infon key="name_6">surname:Matturri;given-names:L</infon><infon key="pub-id_pmid">10373663</infon><infon key="section_type">REF</infon><infon key="source">Oncol Rep</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1999</infon><offset>22456</offset><text>Prognostic significance of different biomarkers in non-small cell lung cancer</text></passage><passage><infon key="fpage">1174</infon><infon key="lpage">1181</infon><infon key="name_0">surname:Fukuse;given-names:T</infon><infon key="name_1">surname:Hirata;given-names:T</infon><infon key="name_2">surname:Naiki;given-names:H</infon><infon key="name_3">surname:Hitomi;given-names:S</infon><infon key="name_4">surname:Wada;given-names:H</infon><infon key="pub-id_doi">10.1002/(SICI)1097-0142(19991001)86:7&lt;1174::AID-CNCR11&gt;3.3.CO;2-#</infon><infon key="pub-id_pmid">10506701</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1999</infon><offset>22534</offset><text>Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of non-small cell lung carcinoma with intrapulmonary metastases</text></passage><passage><infon key="fpage">505</infon><infon key="lpage">510</infon><infon key="name_0">surname:Oyama;given-names:T</infon><infon key="name_1">surname:Osaki;given-names:T</infon><infon key="name_10">surname:Yano;given-names:K</infon><infon key="name_11">surname:Yasumoto;given-names:K</infon><infon key="name_2">surname:Nose;given-names:N</infon><infon key="name_3">surname:Ichiki;given-names:Y</infon><infon key="name_4">surname:Inoue;given-names:M</infon><infon key="name_5">surname:Imoto;given-names:H</infon><infon key="name_6">surname:Yoshimatsu;given-names:T</infon><infon key="name_7">surname:Kodate;given-names:M</infon><infon key="name_8">surname:Uramoto;given-names:H</infon><infon key="name_9">surname:Mizoue;given-names:T</infon><infon key="pub-id_pmid">10769714</infon><infon key="section_type">REF</infon><infon key="source">Anticancer Res</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2000</infon><offset>22709</offset><text>Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma</text></passage><passage><infon key="fpage">1457</infon><infon key="lpage">1465</infon><infon key="name_0">surname:Shiba;given-names:M</infon><infon key="name_1">surname:Kohno;given-names:H</infon><infon key="name_2">surname:Kakizawa;given-names:K</infon><infon key="name_3">surname:Iizasa;given-names:T</infon><infon key="name_4">surname:Otsuji;given-names:M</infon><infon key="name_5">surname:Saitoh;given-names:Y</infon><infon key="name_6">surname:Hiroshima;given-names:K</infon><infon key="name_7">surname:Ohwada;given-names:H</infon><infon key="name_8">surname:Fujisawa;given-names:T</infon><infon key="pub-id_doi">10.1002/1097-0142(20001001)89:7&lt;1457::AID-CNCR7&gt;3.0.CO;2-L</infon><infon key="pub-id_pmid">11013358</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">2000</infon><offset>22847</offset><text>Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma</text></passage><passage><infon key="fpage">169</infon><infon key="lpage">172</infon><infon key="name_0">surname:Pendleton;given-names:N</infon><infon key="name_1">surname:Dixon;given-names:GR</infon><infon key="name_2">surname:Burnett;given-names:HE</infon><infon key="name_3">surname:Occleston;given-names:NL</infon><infon key="name_4">surname:Myskow;given-names:MW</infon><infon key="name_5">surname:Green;given-names:JA</infon><infon key="pub-id_pmid">8102179</infon><infon key="section_type">REF</infon><infon key="source">J Pathol</infon><infon key="type">ref</infon><infon key="volume">170</infon><infon key="year">1993</infon><offset>22979</offset><text>Expression of proliferating cell nuclear antigen (PCNA) in dysplasia of the bronchial epithelium</text></passage><passage><infon key="fpage">996</infon><infon key="lpage">1002</infon><infon key="name_0">surname:Tormanen;given-names:U</infon><infon key="name_1">surname:Nuorva;given-names:K</infon><infon key="name_2">surname:Soini;given-names:Y</infon><infon key="name_3">surname:Paakko;given-names:P</infon><infon key="pub-id_doi">10.1038/sj.bjc.6690159</infon><infon key="pub-id_pmid">10070903</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">79</infon><infon key="year">1999</infon><offset>23076</offset><text>Apoptotic activity is increased in parallel with the metaplasia-dysplasia-carcinoma sequence of the bronchial epithelium</text></passage><passage><infon key="fpage">17</infon><infon key="lpage">25</infon><infon key="name_0">surname:Kitaguchi;given-names:S</infon><infon key="name_1">surname:Takeshima;given-names:Y</infon><infon key="name_2">surname:Nishisaka;given-names:T</infon><infon key="name_3">surname:Inai;given-names:K</infon><infon key="pub-id_pmid">9583279</infon><infon key="section_type">REF</infon><infon key="source">Hiroshima J Med Sci</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1998</infon><offset>23197</offset><text>Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung</text></passage><passage><infon key="fpage">125</infon><infon key="lpage">130</infon><infon key="name_0">surname:Yokose;given-names:T</infon><infon key="name_1">surname:Ito;given-names:Y</infon><infon key="name_2">surname:Ochiai;given-names:A</infon><infon key="pub-id_doi">10.1016/S0169-5002(00)00101-X</infon><infon key="pub-id_pmid">10963842</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2000</infon><offset>23329</offset><text>High prevalence of atypical adenomatous hyperplasia of the lung in autopsy specimens from elderly patients with malignant neoplasms</text></passage><passage><infon key="fpage">73</infon><infon key="lpage">78</infon><infon key="name_0">surname:Todorov;given-names:IT</infon><infon key="name_1">surname:Werness;given-names:BA</infon><infon key="name_2">surname:Wang;given-names:HQ</infon><infon key="name_3">surname:Buddharaju;given-names:LN</infon><infon key="name_4">surname:Todorova;given-names:PD</infon><infon key="name_5">surname:Slocum;given-names:HK</infon><infon key="name_6">surname:Brooks;given-names:JS</infon><infon key="name_7">surname:Huberman;given-names:JA</infon><infon key="pub-id_pmid">9461123</infon><infon key="section_type">REF</infon><infon key="source">Lab Invest</infon><infon key="type">ref</infon><infon key="volume">78</infon><infon key="year">1998</infon><offset>23461</offset><text>HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues</text></passage><passage><infon key="fpage">183</infon><infon key="lpage">190</infon><infon key="name_0">surname:Kearsey;given-names:SE</infon><infon key="name_1">surname:Maiorano;given-names:D</infon><infon key="name_2">surname:Holmes;given-names:EC</infon><infon key="name_3">surname:Todorov;given-names:IT</infon><infon key="pub-id_pmid">8867732</infon><infon key="section_type">REF</infon><infon key="source">Bioessays</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1996</infon><offset>23539</offset><text>The role of MCM proteins in the cell cycle control of genome duplication</text></passage><passage><infon key="fpage">1447</infon><infon key="lpage">1454</infon><infon key="name_0">surname:Lei;given-names:M</infon><infon key="name_1">surname:Tye;given-names:BK</infon><infon key="pub-id_pmid">11282021</infon><infon key="section_type">REF</infon><infon key="source">J Cell Sci</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2001</infon><offset>23612</offset><text>Initiating DNA synthesis: from recruiting to activating the MCM complex</text></passage><passage><infon key="fpage">1643</infon><infon key="lpage">1647</infon><infon key="name_0">surname:Labib;given-names:K</infon><infon key="name_1">surname:Tercero;given-names:JA</infon><infon key="name_2">surname:Diffley;given-names:JFX</infon><infon key="pub-id_doi">10.1126/science.288.5471.1643</infon><infon key="pub-id_pmid">10834843</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">288</infon><infon key="year">2000</infon><offset>23684</offset><text>Uninterrupted MCM2-7 function required for DNA replication fork progression</text></passage><passage><infon key="fpage">2121</infon><infon key="lpage">2132</infon><infon key="name_0">surname:Freeman;given-names:A</infon><infon key="name_1">surname:Morris;given-names:LS</infon><infon key="name_2">surname:Mills;given-names:AD</infon><infon key="name_3">surname:Stoeber;given-names:K</infon><infon key="name_4">surname:Laskey;given-names:RA</infon><infon key="name_5">surname:Williams;given-names:GH</infon><infon key="name_6">surname:Coleman;given-names:N</infon><infon key="pub-id_pmid">10473096</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1999</infon><offset>23760</offset><text>Minichromosome maintenance proteins as biological markers of dysplasia and malignancy</text></passage><passage><infon key="fpage">14932</infon><infon key="lpage">14937</infon><infon key="name_0">surname:Williams;given-names:GH</infon><infon key="name_1">surname:Romanowski;given-names:P</infon><infon key="name_2">surname:Morris;given-names:L</infon><infon key="name_3">surname:Madine;given-names:M</infon><infon key="name_4">surname:Mills;given-names:AD</infon><infon key="name_5">surname:Stoeber;given-names:K</infon><infon key="name_6">surname:Marr;given-names:J</infon><infon key="name_7">surname:Laskey;given-names:RA</infon><infon key="name_8">surname:Coleman;given-names:N</infon><infon key="pub-id_doi">10.1073/pnas.95.25.14932</infon><infon key="pub-id_pmid">9843993</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">1998</infon><offset>23846</offset><text>Improved cervical smear assessment using antibodies against proteins that regulate DNA replication</text></passage><passage><infon key="fpage">34</infon><infon key="lpage">55</infon><infon key="name_0">surname:Matthews;given-names:MJ</infon><infon key="name_1">surname:Mackay;given-names:B</infon><infon key="name_2">surname:Lukeman;given-names:J</infon><infon key="pub-id_pmid">6301064</infon><infon key="section_type">REF</infon><infon key="source">Semin Oncol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1983</infon><offset>23945</offset><text>The pathology of non-small cell carcinoma of the lung</text></passage><passage><infon key="fpage">44</infon><infon key="lpage">53</infon><infon key="name_0">surname:Melamed;given-names:MR</infon><infon key="name_1">surname:Flehinger;given-names:BJ</infon><infon key="name_2">surname:Zaman;given-names:MB</infon><infon key="name_3">surname:Heelan;given-names:RT</infon><infon key="name_4">surname:Perchick;given-names:WA</infon><infon key="name_5">surname:Martini;given-names:N</infon><infon key="pub-id_pmid">6734291</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1984</infon><offset>23999</offset><text>Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York</text></passage><passage><infon key="fpage">746</infon><infon key="lpage">750</infon><infon key="name_0">surname:Fontana;given-names:RS</infon><infon key="name_1">surname:Sanderson;given-names:DR</infon><infon key="name_2">surname:Woolner;given-names:LB</infon><infon key="name_3">surname:Taylor;given-names:WF</infon><infon key="name_4">surname:Miller;given-names:WE</infon><infon key="name_5">surname:Muhm;given-names:JR</infon><infon key="pub-id_pmid">3528436</infon><infon key="section_type">REF</infon><infon key="source">J Occup Med</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1986</infon><offset>24090</offset><text>Lung cancer screening: the Mayo program</text></passage><passage><infon key="fpage">324S</infon><infon key="lpage">325S</infon><infon key="name_0">surname:Tockman;given-names:MS</infon><infon key="pub-id_pmid">3956302</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">89 (Suppl)</infon><infon key="year">1986</infon><offset>24130</offset><text>Survival and mortality from lung cancer in a screened population. The Johns Hopkins Study</text></passage><passage><infon key="fpage">1433</infon><infon key="lpage">1445</infon><infon key="name_0">surname:Todorov;given-names:IT</infon><infon key="name_1">surname:Attaran;given-names:A</infon><infon key="name_2">surname:Kearsey;given-names:SE</infon><infon key="pub-id_pmid">7790346</infon><infon key="section_type">REF</infon><infon key="source">J Cell Biol</infon><infon key="type">ref</infon><infon key="volume">129</infon><infon key="year">1995</infon><offset>24220</offset><text>BM28, a human member of the MCM2-3-5 family, is displaced from chromatin during DNA replication</text></passage></document></collection>